Exact Mass: 257.1215858
Exact Mass Matches: 257.1215858
Found 500 metabolites which its exact mass value is equals to given mass value 257.1215858,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Tolmetin
Tolmetin is only found in individuals that have used or taken this drug. It is a non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. [PubChem]The mode of action of tolmetin is not known. However, studies in laboratory animals and man have demonstrated that the anti-inflammatory action of tolmetin is not due to pituitary-adrenal stimulation. Tolmetin inhibits prostaglandin synthetase in vitro and lowers the plasma level of prostaglandin E in man. This reduction in prostaglandin synthesis may be responsible for the anti-inflammatory action. Tolmetin does not appear to alter the course of the underlying disease in man. M - Musculo-skeletal system > M02 - Topical products for joint and muscular pain > M02A - Topical products for joint and muscular pain > M02AA - Antiinflammatory preparations, non-steroids for topical use M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AB - Acetic acid derivatives and related substances D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents KEIO_ID T044; [MS2] KO009288 D004791 - Enzyme Inhibitors KEIO_ID T044
meclofenoxate
N - Nervous system > N06 - Psychoanaleptics > N06B - Psychostimulants, agents used for adhd and nootropics D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents D002491 - Central Nervous System Agents > D018697 - Nootropic Agents D020011 - Protective Agents
carmofur
C11H16FN3O3 (257.11756379999997)
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01B - Antimetabolites > L01BC - Pyrimidine analogues C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite D000970 - Antineoplastic Agents Same as: D01784 Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC50 of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI)[1][2][3].
4a-Hydroxytetrahydrobiopterin
C9H15N5O4 (257.11239900000004)
Tetrahydrobiopterin (BH4) is essential for catalyzing the conversion of phenylalanine into tyrosine by phenylalanine hydroxylase. During this physiological reaction, the oxidation of BH4 creates 4a-hydroxytetrahydropterin (CAS: 70110-58-6) intermediates and hydrogen peroxide is formed. The hydrogen peroxide and the hydroxytetrahydropterin can both be derived from alternate breakdown routes of a common precursor, the corresponding 4a-hydroperoxytetrahydropterin (PMID: 8323303). Tetrahydrobiopterin (BH4) is essential to catalyze the conversion of phenylalanine to tyrosine by phenylalanine hydroxylase. During this physiological reaction, the oxidation of BH4 creates 4a-hydroxytetrahydropterin intermediates and hydrogen peroxide is formed. The hydrogen peroxide and the hydroxytetrahydropterin can both derive from alternate routes of breakdown of a common precursor, the corresponding 4a-hydroperoxytetrahydropterin. (PMID 8323303) [HMDB]
Tetrahydroneopterin
C9H15N5O4 (257.11239900000004)
Tetrahydroneopterin is a reduced form of neopterin. [HMDB] Tetrahydroneopterin is a reduced form of neopterin.
Indolmycin
A member of the class of 1,3-oxazoles that is 1,3-oxazol-4(5H)-one which is substituted at the 2 and 5-pro-S positions by methylamino and [(1R)-1-(1H-indol-3-yl)ethyl] groups, respectively.
Procarbazine hydrochloride
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D000970 - Antineoplastic Agents
(2R)-2-amino-3-[(2E)-3,7-dimethylocta-2,6-dienyl]sulfanylpropanoic acid
5-Methylcytidine
CONFIDENCE standard compound; INTERNAL_ID 322 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.054 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.053 5-Methylcytidine is a pyrimidine nucleoside detected in multiple biofluids. 5-Methylcytidine is a pyrimidine nucleoside detected in multiple biofluids.
5-Methylcytidine
5-Methylcytidine belongs to the class of organic compounds known as pyrimidine nucleosides. Pyrimidine nucleosides are compounds comprising a pyrimidine base attached to a ribosyl or deoxyribosyl moiety. 5-Methylcytidine is a post-transcriptional modifications found in tRNA, snRNA, and rRNA. It is associated with the genetic change which is involved in the origin of cancer (PMID 6260434). [HMDB] 5-Methylcytidine is a pyrimidine nucleoside detected in multiple biofluids. 5-Methylcytidine is a pyrimidine nucleoside detected in multiple biofluids.
Glycerophosphocholine
Glycerophosphorylcholine (GPC) is a choline derivative and one of the two major forms of choline storage (along with phosphocholine) in the cytosol. Glycerophosphorylcholine is also one of the four major organic osmolytes in renal medullary cells, changing their intracellular osmolyte concentration in parallel with extracellular tonicity during cellular osmoadaptation. As an osmolyte, Glycerophosphorylcholine counteracts the effects of urea on enzymes and other macromolecules. Kidneys (especially medullar cells), which are exposed under normal physiological conditions to widely fluctuating extracellular solute concentrations, respond to hypertonic stress by accumulating the organic osmolytes glycerophosphorylcholine (GPC), betaine, myo-inositol, sorbitol and free amino acids. Increased intracellular contents of these osmolytes are achieved by a combination of increased uptake (myo-inositol and betaine) and synthesis (sorbitol, GPC), decreased degradation (GPC) and reduced osmolyte release. GPC is formed in the breakdown of phosphatidylcholine (PtC). This pathway is active in many body tissues, including mammary tissue. Choline alfoscerate, also known as glycerophosphocholine or choline glycerophosphate, is a member of the class of compounds known as glycerophosphocholines. Glycerophosphocholines are lipids containing a glycerol moiety carrying a phosphocholine at the 3-position. Choline alfoscerate is slightly soluble (in water) and a moderately acidic compound (based on its pKa). Choline alfoscerate can be found in a number of food items such as radish, strawberry guava, yellow pond-lily, and pepper (c. baccatum), which makes choline alfoscerate a potential biomarker for the consumption of these food products. L-Alpha glycerylphosphorylcholine (alpha-GPC, choline alfoscerate) is a natural choline compound found in the brain. It is also a parasympathomimetic acetylcholine precursor which may have potential for the treatment of Alzheimers disease and other dementias . N - Nervous system > N07 - Other nervous system drugs > N07A - Parasympathomimetics C78272 - Agent Affecting Nervous System > C47796 - Cholinergic Agonist D013501 - Surface-Active Agents > D054709 - Lecithins COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS sn-Glycero-3-phosphocholine (Choline Alfoscerate) is a precursor in the biosynthesis of brain phospholipids and increases the bioavailability of choline in nervous tissue. sn-Glycero-3-phosphocholine (Choline Alfoscerate) has significant effects on cognitive function with a good safety profile and tolerability, and is effective in the treatment of Alzheimer's disease and dementia[1][2].
Pyro-L-glutaminyl-L-glutamine
Pyro-L-glutaminyl-L-glutamine is found in fruits. Pyro-L-glutaminyl-L-glutamine is a constituent of the seeds of Dolichos biflorus (papadi). Constituent of the seeds of Dolichos biflorus (papadi). Pyro-L-glutaminyl-L-glutamine is found in fruits.
Coumaperine
Coumaperine is found in herbs and spices. Coumaperine is isolated from the fruits of pepper (Piper nigrum) (Piperaceae). Isolated from the fruits of pepper (Piper nigrum) (Piperaceae). Coumaperine is found in herbs and spices.
2-Hexenoylcarnitine
2-Hexenoylcarnitine is an acylcarnitine. More specifically, it is an 2-hexenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-Hexenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2-hexenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular 2-hexenoylcarnitine is elevated in the blood or plasma of individuals with obesity in aldolenscens (PMID: 26910390). It is also decreased in the blood or plasma of individuals with adolescent idiopathic scoliosis (PMID: 26928931). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. A human metabolite taken as a putative food compound of mammalian origin [HMDB]
3-Methylcytidine
3-Methylcytidine belongs to the class of organic compounds known as pyrimidine nucleosides. These are compounds comprising a pyrimidine base attached to a ribosyl or deoxyribosyl moiety. 3-Methylcytidine is a potential urinary biomarker of whole grain intake (PMID: 27805021). 3-Methylcytidine has been identified in the human placenta (PMID: 32033212). 3-Methylcytidine, a urinary nucleoside, can be used as a biomarker of four different types of cancer: lung cancer, gastric cancer, colon cancer, and breast cancer[1].
4-Hexenoylcarnitine
4-Hexenoylcarnitine is an acylcarnitine. More specifically, it is an hex-4-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Hexenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-Hexenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular 4-Hexenoylcarnitine is elevated in the blood or plasma of individuals with obesity in aldolenscens (PMID: 26910390). It is also decreased in the blood or plasma of individuals with adolescent idiopathic scoliosis (PMID: 26928931). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(3E)-Hexenoylcarnitine
(3E)-Hexenoylcarnitine is an acylcarnitine. More specifically, it is an (3E)-hex-3-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (3E)-Hexenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (3E)-Hexenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (3E)-Hexenoylcarnitine is elevated in the blood or plasma of individuals with obesity in aldolenscens (PMID: 26910390). It is also decreased in the blood or plasma of individuals with adolescent idiopathic scoliosis (PMID: 26928931). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
1-[(2S,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-imino-3-methylpyrimidin-2-one
2'-O-Methylcytidine
2'-O-Methylcytidine is a 2'-substituted nucleoside as a inhibitor of HCV replication. 2'-O-Methylcytidine inhibits RNA-dependent RNA polymerase (NS5B)-catalyzed RNA synthesis in vitro, in a manner that is competitive with substrate nucleoside triphosphate[1].
2'-C-Methylcytidine
3-(Aminomethyl)-2,5,9-trimethyl-7H-furo[3,2-g]chromen-7-one
D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D003432 - Cross-Linking Reagents D011838 - Radiation-Sensitizing Agents > D017319 - Photosensitizing Agents > D011564 - Furocoumarins D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents D003879 - Dermatologic Agents
benserazide
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents D004791 - Enzyme Inhibitors C471 - Enzyme Inhibitor
Carmofur
C11H16FN3O3 (257.11756379999997)
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01B - Antimetabolites > L01BC - Pyrimidine analogues C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite D000970 - Antineoplastic Agents Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC50 of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI)[1][2][3].
Chlorazine
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents D005765 - Gastrointestinal Agents > D000932 - Antiemetics
Coumarin 10
Glycerylphosphorylcholine
Glycerophosphorylcholine (GPC) is a choline derivative and one of the two major forms of choline storage (along with phosphocholine) in the cytosol. Glycerophosphorylcholine is also one of the four major organic osmolytes in renal medullary cells, changing their intracellular osmolyte concentration in parallel with extracellular tonicity during cellular osmoadaptation. As an osmolyte, Glycerophosphorylcholine counteracts the effects of urea on enzymes and other macromolecules. Kidneys (especially medullar cells), which are exposed under normal physiological conditions to widely fluctuating extracellular solute concentrations, respond to hypertonic stress by accumulating the organic osmolytes glycerophosphorylcholine (GPC), betaine, myo-inositol, sorbitol and free amino acids. Increased intracellular contents of these osmolytes are achieved by a combination of increased uptake (myo-inositol and betaine) and synthesis (sorbitol, GPC), decreased degradation (GPC) and reduced osmolyte release. [HMDB] D013501 - Surface-Active Agents > D054709 - Lecithins sn-Glycero-3-phosphocholine (Choline Alfoscerate) is a precursor in the biosynthesis of brain phospholipids and increases the bioavailability of choline in nervous tissue. sn-Glycero-3-phosphocholine (Choline Alfoscerate) has significant effects on cognitive function with a good safety profile and tolerability, and is effective in the treatment of Alzheimer's disease and dementia[1][2].
Medifoxamine
C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist Medifoxamine is a monoamine re-uptake inhibiting antidepressive agent which preferentially inhibits dopamine reuptake[1].
4-Amino-1-[(2R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidin-2-one
3-[2-Carboxyprop-1-enyl(ethoxycarbonyl)amino]-2-methylprop-2-enoic acid
Tezacitabine
4alpha-hydroxy-tetrahydrobiopterin
C9H15N5O4 (257.11239900000004)
4alpha-hydroxy-tetrahydrobiopterin, also known as 4a-hthb, belongs to biopterins and derivatives class of compounds. Those are coenzymes containing a 2-amino-pteridine-4-one derivative. They are mainly synthesized in several parts of the body, including the pineal gland. 4alpha-hydroxy-tetrahydrobiopterin is slightly soluble (in water) and a very weakly acidic compound (based on its pKa). 4alpha-hydroxy-tetrahydrobiopterin can be found in a number of food items such as garden cress, japanese pumpkin, tronchuda cabbage, and arctic blackberry, which makes 4alpha-hydroxy-tetrahydrobiopterin a potential biomarker for the consumption of these food products. In humans, 4alpha-hydroxy-tetrahydrobiopterin is involved in few metabolic pathways, which include disulfiram action pathway, phenylalanine and tyrosine metabolism, tryptophan metabolism, and tyrosine metabolism. 4alpha-hydroxy-tetrahydrobiopterin is also involved in several metabolic disorders, some of which include hawkinsinuria, monoamine oxidase-a deficiency (MAO-A), phenylketonuria, and tyrosinemia type 3 (TYRO3). 4α-hydroxy-tetrahydrobiopterin, also known as 4a-hthb, belongs to biopterins and derivatives class of compounds. Those are coenzymes containing a 2-amino-pteridine-4-one derivative. They are mainly synthesized in several parts of the body, including the pineal gland. 4α-hydroxy-tetrahydrobiopterin is slightly soluble (in water) and a very weakly acidic compound (based on its pKa). 4α-hydroxy-tetrahydrobiopterin can be found in a number of food items such as garden cress, japanese pumpkin, tronchuda cabbage, and arctic blackberry, which makes 4α-hydroxy-tetrahydrobiopterin a potential biomarker for the consumption of these food products. In humans, 4α-hydroxy-tetrahydrobiopterin is involved in few metabolic pathways, which include disulfiram action pathway, phenylalanine and tyrosine metabolism, tryptophan metabolism, and tyrosine metabolism. 4α-hydroxy-tetrahydrobiopterin is also involved in several metabolic disorders, some of which include hawkinsinuria, monoamine oxidase-a deficiency (MAO-A), phenylketonuria, and tyrosinemia type 3 (TYRO3).
benserazide
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents D004791 - Enzyme Inhibitors C471 - Enzyme Inhibitor CONFIDENCE standard compound; EAWAG_UCHEM_ID 2853
3-Methylcytidine
3-Methylcytidine, a urinary nucleoside, can be used as a biomarker of four different types of cancer: lung cancer, gastric cancer, colon cancer, and breast cancer[1].
3alpha-cinnamoyloxynortropane|nortropinyl cinnamate
5-Hydroxymethyldeoxycytidin|O5-hydroxymethyl-2-deoxy-cytidine
(2E,4E)-N-[2-(methylsulfinyl)ethyl]-2,4-decadienamide
A natural product found in Piper boehmeriaefolium.
(2S)-N-cis-cinnamoyl-2-(2-oxo-propyl)-pyrrolidine|(2S)-N-cis-cinnamoyl-2-oxopropyrrolidine|cis-dendrochrysanine
4-methoxy-3-(3-methyl-2-oxobut-3-enyl)quinolin-2(1H)-one|limonelone
(8aR,9R,11R,12aR)-6,7,8,8a,9,10,11,12-octahydro-11-methyl-1,9-ethanobenzo[i]quinolizin-13,14-dione|huperzine E
N-(beta-Glutaminylaminoethyl)-2H-Oxo-5(4H)-Isoxazolone
9-methoxy-2,2-dimethyl-6-hydro-2H-pyrano[5,6-c]quinolin-5-one
relative retention time with respect to 9-anthracene Carboxylic Acid is 1.161 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.159
2-O-Methylcytidine
relative retention time with respect to 9-anthracene Carboxylic Acid is 0.053 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.052 2'-O-Methylcytidine is a 2'-substituted nucleoside as a inhibitor of HCV replication. 2'-O-Methylcytidine inhibits RNA-dependent RNA polymerase (NS5B)-catalyzed RNA synthesis in vitro, in a manner that is competitive with substrate nucleoside triphosphate[1].
C15H15NO3_9-Methoxy-2,2-dimethyl-2,6-dihydro-5H-pyrano[3,2-c]quinolin-5-one
C14H15N3O2_2,5-Piperazinedione, 3-(1H-indol-3-ylmethyl)-6-methyl
3-O-Methylcytidine
3′-O-Methylcytidine is a cytidine analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities[1].
9-Methoxy-2,2-dimethyl-2,6-dihydro-pyrano[3,2-c]quinolin-5-one
Medifoxamine
C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist Medifoxamine is a monoamine re-uptake inhibiting antidepressive agent which preferentially inhibits dopamine reuptake[1].
meclofenoxate
N - Nervous system > N06 - Psychoanaleptics > N06B - Psychostimulants, agents used for adhd and nootropics D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents D002491 - Central Nervous System Agents > D018697 - Nootropic Agents D020011 - Protective Agents
formetanate hydrochloride
C11H16ClN3O2 (257.09309859999996)
Mefenamic acid Metabolite (Anthranilic acid, N-(a3-hydroxy-2,3-xylyl)-)
Glycerophosphocholine
sn-Glycero-3-phosphocholine (Choline Alfoscerate) is a precursor in the biosynthesis of brain phospholipids and increases the bioavailability of choline in nervous tissue. sn-Glycero-3-phosphocholine (Choline Alfoscerate) has significant effects on cognitive function with a good safety profile and tolerability, and is effective in the treatment of Alzheimer's disease and dementia[1][2].
1-tert-Butyl 3-methyl 4-oxopiperidine-1,3-dicarboxylate
2-(dimethylamino)ethyl 2-methylprop-2-enoate,methyl 2-methylprop-2-enoate
1,2-dimethyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride
7-Benzyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2,4(1H,3H)-dione
9-ETHYL-8-OXO-6,7,8,9-TETRAHYDRO-5H-CARBAZOLE-3-CARBOXYLIC ACID
(R)-TERT-BUTYL 3-(2-METHOXY-2-OXOETHYL)PIPERIDINE-1-CARBOXYLATE
(2R,6R,8S,12S)-1-AZA-10-OXO-12-PHENYLTRICYCLO[6.4.01,8.02,6]DODECAN-9-ONE
Indolidan
C78274 - Agent Affecting Cardiovascular System > C78322 - Cardiotonic Agent C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor
1-(TERT-BUTOXYCARBONYL)-3-ETHYLPIPERIDINE-3-CARBOXYLIC ACID
3-(2-DIPROPYLAMINO-ETHYL)-PHENOL HYDROCHLORIDE
C14H24ClNO (257.15463239999997)
3-Amino-N,N-diethyl-4-(methylamino)benzenesulfonamide
4-(4-hydroxypiperidin-1-yl)quinazoline-6-carbaldehyde
3-(N-ethyl-3-methylanilino)propane-1-sulfonic acid
3-(2-Carboxyethyl)piperidine-1-carboxylic acid tert-butyl ester
3-AMINO-N-((DIMETHYLAMINO)ETHYL)-N-METHYLBENZENESULFONAMIDE
4-AMINO-N-((DIMETHYLAMINO)ETHYL)-N-METHYLBENZENESULFONAMIDE
6-Hydroxy-1,2,3,4-tetrahydro-isoquinoline-1-carboxylic acid ethyl ester hydrochloride
Isoquinoline,6,7-diethoxy-1,2,3,4-tetrahydro-, hydrochloride (1:1)
1-(TERT-BUTOXYCARBONYL)-2-METHYLAZEPANE-2-CARBOXYLIC ACID
1-(tert-Butoxycarbonyl)-4-methylazepane-4-carboxylic acid
1-tert-butyl-2,3,6,7-tetrahydro-1H-phosphepin-1-ium,tetrafluoroborate
1-tert-butyl 2-ethyl 5-oxopyrrolidine-1,2-dicarboxylate
1-[3-(diethylaminomethyl)-4-hydroxyphenyl]ethanone,hydrochloride
4-Benzyl-2-morpholinecarboxylic Acid Hydrochloride
1-(TERT-BUTOXYCARBONYL)-6,6-DIMETHYLPIPERIDINE-3-CARBOXYLIC ACID
alpha-(N,N-Dimethylamino)ethylferrocene
C14H19FeN (257.08668040000003)
Methyl (2S,4S)-4-phenoxy-2-pyrrolidinecarboxylate(HCl)
1-METHYL-3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-1H-INDOLE
6-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole
acetic acid,1-methyl-5H-pyrido[4,3-b]indol-3-amine
(S)-3-(3-ACETYL-4-HYDROXY-PHENYL)-2-AMINO-PROPIONICACIDMETHYLESTER
1-TERT-BUTYL 2-METHYL 2-(2-OXOETHYL)AZETIDINE-1,2-DICARBOXYLATE
1-phenyl-7-(trifluoromethyl)azepan-2-one
C13H14F3NO (257.10274300000003)
(R)-4-(6-METHOXYNAPHTHALEN-2-YL)-4-METHYLOXAZOLIDIN-2-ONE
(PIPERIDIN-4-YL)(4-TRIFLUOROMETHYLPHENYL)METHANONE
C13H14F3NO (257.10274300000003)
trimethyl-[(3-trimethylsilyloxy-1,2,4-triazin-5-yl)oxy]silane
ethene,(Z)-4-ethoxy-4-oxobut-2-enoic acid,2-methylprop-2-enoate
1-(6-Methylpyridin-3-yl)-2-(4-(Methylthio)phenyl)ethanone
N-[2-(1,2,6,7-Tetrahydro-8H-indeno[5,4-b]furan-8-ylidene)ethyl]propanamide
Isoquinoline,3,4-dihydro-1-(phenylmethyl)-, hydrochloride (1:1)
Ethyl 3-[benzyl(methyl)amino]-2,2-difluoropropanoate
2-(2-Carboxyethyl)piperidine-1-carboxylic acid tert-butyl ester
3-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)-5-nitro-1H-indole
1-tert-Butoxycarbonylamino-cycloheptanecarboxylic acid
ETHYL 1-(ETHOXYCARBONYL)-4-OXO-3-PIPERIDINEACETATE
2,5-dimethyl-4-(morpholinomethyl)phenol hydrochloride
3-[(4,6-DIMETHYLPYRIMIDIN-2-YL)(METHYL)AMINO]BENZOICACID
(E)-METHYL 3-(2-((TERT-BUTYLDIMETHYLSILYLOXY)-METHYL)FURO[3,2-B]PYRIDIN-6-YL)ACRYLATE
(S)-1-tert-butyl 2-methyl 4-oxopiperidine-1,2-dicarboxylate
ethyl 1-(tert-butoxycarbonylamino)-3-oxo-cyclobutanecarboxylate
2-C-Methylcytidine
NM107 (2'-C-Methylcytidine) is an nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, the EC50 of NM107 in the wild-type replicon cells is 1.85 μM[1][2].
Carbamic acid, (4-methoxyphenyl)-, phenylmethyl ester (9CI)
3-(Dimethylamino)-1-(3-methoxyphenyl)-2-methyl-1-propanone hydrochloride
N-Trimethoxysilylpropyl-N,N,N-Trimethyl Ammonium Chloride
(r)-2-tert-butoxycarbonylamino-3-cyclopentyl-propionic acid
methyl 1-pyridin-2-yl-4,5,6,7-tetrahydroindazole-5-carboxylate
2-[[4-[bis(2-hydroxyethyl)amino]phenyl]methylidene]propanedinitrile
TERT-BUTYL 2-(2-METHOXY-2-OXOETHYL)PIPERAZINE-1-CARBOXYLATE
5,5-DIMETHYL-2-PHENYL-5,6-DIHYDROBENZO[D]THIAZOL-7(4H)-ONE
METHYL 5-CYANO-2-OXO-5-PHENYLCYCLOHEXANECARBOXYLATE
(2-AMINO-2-PHENYL-ETHYL)-CARBAMICACIDTERT-BUTYLESTER
Cyclohexanecarboxylic acid, 1-[[(1,1-dimethylethoxy)carbonyl]amino]-4-oxo- (9CI)
METHYL 6-METHOXY-1,2,3,4-TETRAHYDROQUINOLINE-2-CARBOXYLATE HCL
8-ACETYL-3A,4,5,9B-TETRAHYDRO-3 H-CYCLOPENTA[ C ]QUINOLINE-4-CARBOXYLIC ACID
Ethyl 2-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)acetate hydrochloride
C11H16ClN3O2 (257.09309859999996)
Ethyl 2-(5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)acetate hydrochloride
C11H16ClN3O2 (257.09309859999996)
tert-butyl 2-(hydroxymethyl)-1-oxa-7-azaspiro[3.5]nonane-7-carboxylate
4-Oxo-1,2-piperidinedicarboxylic acid 1-(tert-butyl) 2-methyl ester
2-benzyl-4,6,7,7a-tetrahydro-3aH-isoindole-1,3,5-trione
3-Furancarboxamide,2-methyl-N-[2-methyl-6-(1-methylethyl)phenyl]-(9CI)
Acetamide,2-chloro-N,N-dicyclohexyl-
C14H24ClNO (257.15463239999997)
6-Benzyl-5,6,7,8-tetrahydro-1H-pyrido[4,3-d]pyrimidine-2,4-dione
Acetamide,2-chloro-N-[2-(3,4-dimethoxyphenyl)ethyl]-
1-TERT-BUTYL 4-METHYL 3-OXOPIPERIDINE-1,4-DICARBOXYLATE
N4,N4-DIMETHYL-N6-(PIPERIDIN-4-YL)PYRIMIDINE-4,6-DIAMINE HYDROCHLORIDE
(S)-TERT-BUTYL 2-(2-METHOXY-2-OXOETHYL)PIPERIDINE-1-CARBOXYLATE
Ethyl (1S,2R)-2-(Boc-amino)cyclopentanecarboxylate
Ethyl (1R,2S)-2-(Boc-amino)cyclopentanecarboxylate
(s)-(-)-n,n-dimethyl-1-ferrocenylethylamine
C14H19FeN (257.08668040000003)
[(1R)-1-(Dimethylamino)ethyl]ferrocene
C14H19FeN (257.08668040000003)
(S)-TERT-BUTYL1-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3-YL)ETHYLCARBAMATE
2-AMINO-1-(4-ISOPROPYL-PIPERAZIN-1-YL)-ETHANONE 2 HCL
Phosphoramidic acid,(2-phenylethyl)-, diethyl ester (9CI)
C12H20NO3P (257.11807400000004)
2-[2-([1,3,4]THIADIAZOL-2-YLCARBAMOYL)-ETHYL]-PENTANOIC ACID
2-(cis-4-((tert-Butoxycarbonyl)amino)cyclohexyl)acetic acid
1-ETHYL-6,7-DIMETHOXY-1,2,3,4-TETRAHYDROISOQUINOLINE HYDROCHLORIDE
Pyrido[2,3-b]pyrazin-7-ylboronic acid pinacol ester
3-(TERT-BUTOXYCARBONYL(CYCLOPENTYL)AMINO)PROPANOICACID
3-(1-(tert-Butoxycarbonyl)piperidin-4-yl)propanoic acid
1-O-tert-butyl 2-O-methyl 2-methylpiperidine-1,2-dicarboxylate
4-OXO-2-PIPERIDIN-1-YL-4H-PYRIDO[1,2-A]PYRIMIDINE-3-CARBALDEHYDE
ethyl (E)-3-phenyl-2-(1,2,4-triazol-1-ylmethyl)prop-2-enoate
1H-1-Benzazepine-1-carboxamide,2,3,4,5-tetrahydro-N-1H-1,2,4-triazol-3-yl-
tert-butyl 4-(2-methoxy-2-oxo-ethyl)piperidine-1-carboxylate
4-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole
N-Benzyl-1-(4-fluorophenyl)-2-methyl-2-aminopropane
Benzoic acid, 2-(3-formyl-2,5-dimethyl-1H-pyrrol-1-yl)-, methyl ester (9CI)
1-O-tert-butyl 3-O-methyl 6-methylpiperidine-1,3-dicarboxylate
3-Pyrrolidinecarboxylic acid, 4-(3-methoxyphenyl)-, hydrochloride (1:1), (3S,4R)-
(1S,3S,4R)-methyl 2-((R)-1-phenylethyl)-2-azabicyclo[2.2.1]hept-5-ene-3-carboxylate
1-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole
1-METHYL-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-1H-INDOLE
1-Methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole
1-((3AR,6S,7AS)-8,8-DIMETHYL-2,2-DIOXIDOHEXAHYDRO-1H-3A,6-METHANOBENZO[C]ISOTHIAZOL-1-YL)ETHANONE
Benzyl (2S)-3-methyl-2-(methylamino)butanoatehydrochloride
Hydrazinecarbothioamide,N-(4-cyclopropyl-1-naphthalenyl)-
4-Hydroxy-1-(2-C-Methyl--D-ribofuranosyl)- 2(1H)-pyridinone
4-Benzyl-morpholine-3-carboxylic acid hydrochloride
Tapentadole HCl
C14H24ClNO (257.15463239999997)
D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D018759 - Adrenergic Uptake Inhibitors D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D049990 - Membrane Transport Modulators
(4-(N-Isopropylsulfamoyl)-2-methylphenyl)boronic acid
(2-Methyl-4-(N-propylsulfamoyl)phenyl)boronic acid
(S)-3-Benzyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-carboxylic acid
1-TERT-BUTYL 2-METHYL 3-OXOPIPERIDINE-1,2-DICARBOXYLATE
FURAN-2-YLMETHYL-[1-(4-METHOXY-PHENYL)-BUT-3-ENYL]-AMINE
4-[(4,6-DIMETHYLPYRIMIDIN-2-YL)(METHYL)AMINO]BENZOICACID
methyl 2-methylprop-2-enoate,prop-2-enenitrile,styrene
Tezacitabine
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2150 - Ribonucleotide Reductase Inhibitor D011838 - Radiation-Sensitizing Agents D000970 - Antineoplastic Agents D004791 - Enzyme Inhibitors
4-Amino-5-methyl-1-pentofuranosyl-2(1h)-pyrimidinone
Fluorocyclopentenylcytosine
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2150 - Ribonucleotide Reductase Inhibitor
3-(1H-Indol-3-ylmethyl)-6-methyl-2,5-piperazinedione
4-Amino-1-[4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]pyrimidin-2-one
N4-Methylcytidine
N4-Methylcytidine (Nsc518744) is a cytidine nucleoside analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities[1].
Ala-Ala-Pro
A tripeptide composed of two L-alanyl units and an L-proline joined by peptide linkages.
(E)-1-(benzofuran-2-yl)-3-morpholinoprop-2-en-1-one
Choline alfoscerate
A member of the class of phosphocholines that is the choline ester of sn-glycero-3-phosphate. It is one of the major osmolyte in the renal medullary cells. N - Nervous system > N07 - Other nervous system drugs > N07A - Parasympathomimetics C78272 - Agent Affecting Nervous System > C47796 - Cholinergic Agonist D013501 - Surface-Active Agents > D054709 - Lecithins COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS sn-Glycero-3-phosphocholine (Choline Alfoscerate) is a precursor in the biosynthesis of brain phospholipids and increases the bioavailability of choline in nervous tissue. sn-Glycero-3-phosphocholine (Choline Alfoscerate) has significant effects on cognitive function with a good safety profile and tolerability, and is effective in the treatment of Alzheimer's disease and dementia[1][2].
5-[(1R)-1-(1H-indol-3-yl)ethyl]-2-(methylamino)-1,3-oxazol-4-ol
(6R)-L-threo-5,6,7,8-tetrahydroneopterin
C9H15N5O4 (257.11239900000004)
(5R)-6-(2-amino-1-carbamoyl-4,5-dihydroimidazol-4-yl)-5-hydroxyhexanoate
5-amino-5-oxo-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoic acid
9-Hydroxy-7,7-dimethyl-6,8-dihydrocyclopenta[g]isoquinoline-5-carboxylic acid
4-amino-1-[(3E)-3-(fluoromethylidene)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
3-[2-Carboxyprop-1-enyl(ethoxycarbonyl)amino]-2-methylprop-2-enoic acid
5-propoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[3,2-b]pyridine
N-(4-phenylmethoxyphenyl)carbamic acid methyl ester
pyrazolo[5,1-c][1,2,4]benzotriazin-8-yl N,N-dimethylcarbamate
1-(2-Fluoro-3,4-dimethoxyphenyl)-2-(propan-2-ylamino)ethanol
1-(3-Fluoro-4,5-dimethoxyphenyl)-2-(propan-2-ylamino)ethanol
7,7-Dimethyl-2-(1-pyrrolidinyl)-5,8-dihydropyrano[4,3-b]pyridine-3-carbonitrile
N-(3-pyridinyl)-5,6,7,8-tetrahydro-4H-cyclohepta[d]isoxazole-3-carboxamide
5-[(4-Methyl-1-piperidinyl)methyl]-3-phenyl-1,2,4-oxadiazole
2-[(2S,3S,6S)-2-(hydroxymethyl)-3-(1-oxopropylamino)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester
2-[(2S,3R,6R)-2-(hydroxymethyl)-3-(1-oxopropylamino)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester
2-[(2S,3R,6S)-2-(hydroxymethyl)-3-(1-oxopropylamino)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester
2-[(2R,3R,6R)-2-(hydroxymethyl)-3-(1-oxopropylamino)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester
2-[(2R,3S,6S)-2-(hydroxymethyl)-3-(1-oxopropylamino)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester
2-[(2R,3S,6R)-2-(hydroxymethyl)-3-(1-oxopropylamino)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester
2-[(2S,3S,6R)-2-(hydroxymethyl)-3-(1-oxopropylamino)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester
2-[(2R,3R,6S)-2-(hydroxymethyl)-3-(1-oxopropylamino)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester
(2S)-2,3-dihydroxypropyl 2-(trimethylazaniumyl)ethyl phosphate
2-Aminoethyl (2-hydroxy-3-propoxypropyl) hydrogen phosphate
4-Acetonyl-3-methyl-1-para-tolyl-3-pyrroline-2,5-dione
tolmetin
M - Musculo-skeletal system > M02 - Topical products for joint and muscular pain > M02A - Topical products for joint and muscular pain > M02AA - Antiinflammatory preparations, non-steroids for topical use M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AB - Acetic acid derivatives and related substances D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D004791 - Enzyme Inhibitors
4a-Hydroxytetrahydrobiopterin
C9H15N5O4 (257.11239900000004)
A tetrahydropterin that is 5,6,7,8-tetrahydrobiopterin carrying an additional hydroxy substituent at the 4a-position. A 4a-hydroxytetrahydrobiopterin which has R configuration at position 6 and in which the dihydroxypropyl substituent has L-erythro configuration.
Pyroglutamylglutamine
A dpeptide obtained by formal condensation of the carboxy group of L-pyroglutamine with the amino group of L-glutamine
Glycerylphosphorylcholine
D013501 - Surface-Active Agents > D054709 - Lecithins
2-Amino-6-(1,2-dihydroxypropyl)-4a-hydroxy-1,5,6,7-tetrahydropteridin-4-one
C9H15N5O4 (257.11239900000004)
9-methoxy-2,2-dimethyl-6H-pyrano[3,2-c]quinolin-5-one
(5r)-5-[(1s)-1-(1h-indol-3-yl)ethyl]-2-(methylimino)-5h-1,3-oxazol-4-ol
(2s)-2-amino-4-{[2-(5-oxo-1,2-oxazol-2-yl)ethyl]-c-hydroxycarbonimidoyl}butanoic acid
(1s,10s,11s)-7-methyl-2-oxa-15-azatetracyclo[8.7.0.0³,⁸.0¹¹,¹⁵]heptadeca-3(8),4,6-trien-9-one
3-oxa-8-azatricyclo[3.2.1.0²,⁴]octan-6-yl 2-phenylprop-2-enoate
(2s,3ar,4r,7ar)-4-hydroxy-6-(methoxycarbonyl)-2-methyl-3a,4,5,7a-tetrahydro-1,3-benzodioxole-2-carboximidic acid
8-azabicyclo[3.2.1]octan-3-yl 2-phenylprop-2-enoate
(1r,3s,5s)-8-azabicyclo[3.2.1]octan-3-yl (2e)-3-phenylprop-2-enoate
2-hydroxy-n-[2-(4-hydroxyphenyl)ethyl]benzenecarboximidic acid
(4e)-5-hydroxy-4-[(2e,4e,8e)-1-hydroxy-4-methyldeca-2,4,8-trien-6-yn-1-ylidene]-2h-pyrrol-3-one
4-[2-(dimethylamino)ethyl]-4-(4-hydroxyphenyl)cyclohexa-2,5-dien-1-one
(3r,6s)-3-(1h-indol-3-ylmethyl)-6-methyl-3,6-dihydropyrazine-2,5-diol
5-[(1r)-1-(1h-indol-3-yl)ethyl]-2-(methylimino)-5h-1,3-oxazol-4-ol
(2e)-5-(acetyloxy)-n-(3-methoxy-3-oxopropyl)-3-methylpent-2-enimidic acid
8-azabicyclo[3.2.1]octan-3-yl 3-phenylprop-2-enoate
5-[1-(1h-indol-3-yl)ethyl]-2-(methylimino)-5h-1,3-oxazol-4-ol
(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl 1h-pyrrole-2-carboxylate
5-[(7s)-7-hydroxy-4-methyl-5h,6h,7h-cyclopenta[c]pyridin-1-yl]benzene-1,3-diol
(1r,11r)-7-methyl-2-oxa-15-azatetracyclo[8.7.0.0³,⁸.0¹¹,¹⁵]heptadeca-3(8),4,6-trien-9-one
(2r)-6-(benzylimino)-2-hydroxy-2,5-dimethylcyclohex-4-ene-1,3-dione
(1r,3s,5s)-8-azabicyclo[3.2.1]octan-3-yl 2-phenylprop-2-enoate
1-[2-(2-oxopropyl)pyrrolidin-1-yl]-3-phenylprop-2-en-1-one
5-(4-hydroxyphenyl)-1-(piperidin-1-yl)penta-2,4-dien-1-one
(5s)-5-[(1r)-1-(1h-indol-3-yl)ethyl]-2-(methylimino)-5h-1,3-oxazol-4-ol
(2s)-1-[(2s)-2-{[(2s)-2-amino-1-hydroxypropylidene]amino}propanoyl]pyrrolidine-2-carboxylic acid
2-methyl-4-phenyl-10-oxa-4-azatricyclo[5.2.1.0²,⁶]decane-3,5-dione
15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadeca-7,9-diene-11,12-dione
2-[(8ar)-1,2,3,5,6,8a-hexahydroindolizine-8-carbonyl]-3-methylphenol
(4as)-6-hydroxy-3,4a,5-trimethyl-1h,4h-cyclohexa[f]indole-2,7-dione
2,4,5-trihydroxy-3,6-bis(2-methylpropyl)-1-oxo-1h-1λ⁵-pyrazin-1-ylium
(2s)-2-hydroxy-2-isopropyl-7-methylfuro[3,2-h]isoquinolin-3-one
(2z)-1-[(2s)-2-(2-oxopropyl)pyrrolidin-1-yl]-3-phenylprop-2-en-1-one
5-{7-hydroxy-4-methyl-5h,6h,7h-cyclopenta[c]pyridin-1-yl}benzene-1,3-diol
(3s,6s)-3-(1h-indol-3-ylmethyl)-6-methyl-3,6-dihydropyrazine-2,5-diol
2-[(5s)-5-hydroxy-4-methyl-5h,6h,7h-cyclopenta[c]pyridin-1-yl]benzene-1,4-diol
1-hydroxy-3-methoxy-1,2-dimethyl-9h-carbazol-4-one
2-[(5r)-5-hydroxy-4-methyl-5h,6h,7h-cyclopenta[c]pyridin-1-yl]benzene-1,4-diol
4-methoxy-1-methyl-3-(3-methylbut-2-en-1-yl)quinolin-2-one
6-hydroxy-3,4a,5-trimethyl-1h,4h-cyclohexa[f]indole-2,7-dione
(2e)-1-[(2s)-2-(2-oxopropyl)pyrrolidin-1-yl]-3-phenylprop-2-en-1-one
5-hydroxy-4-(1-hydroxy-4-methyldeca-2,4,8-trien-6-yn-1-ylidene)-2h-pyrrol-3-one
5-(acetyloxy)-n-(3-methoxy-3-oxopropyl)-3-methylpent-2-enimidic acid
4-{[(2e)-5-(acetyloxy)-1-hydroxy-3-methylpent-2-en-1-ylidene]amino}butanoic acid
7-hydroxy-2,2,6-trimethylpyrano[3,2-c]quinolin-5-one
(1s,12s,14r)-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6(17),7,9,15-tetraen-14-ol
2-amino-4-{[2-(5-oxo-1,2-oxazol-2-yl)ethyl]-c-hydroxycarbonimidoyl}butanoic acid
6-(hydroxymethyl)-2,2-dimethylpyrano[3,2-c]quinolin-5-one
6-(benzylimino)-2-hydroxy-2,5-dimethylcyclohex-4-ene-1,3-dione
(4as,6r)-6-[(1r,2s)-1,2-dihydroxypropyl]-2-imino-1,5,6,7-tetrahydropteridine-4,4a-diol
C9H15N5O4 (257.11239900000004)